Researchers are developing a new, first-in-class agent that has stopped the growth of estrogen receptor-positive (ER-positive) breast cancer in its tracks. The new agent is a molecule called ERX-11 that has blocked the growth of recurring breast cancer tumors. Ratna Vadlamudi, Ph.D., from UT Health San Antonio, is principal investigator of a study describing the new findings, published Aug. 8 in the journal eLIFE.

Link: Drug for recurring ER-positive breast cancer

Source: Gynecology Science Daily

Leave a Reply

Your email address will not be published.